Overview

The marketing authorisation for LeukoScan has been withdrawn at the request of the marketing authorisation holder.

български (BG) (716 KB - PDF)

View

español (ES) (517.76 KB - PDF)

View

čeština (CS) (685.63 KB - PDF)

View

dansk (DA) (517.71 KB - PDF)

View

Deutsch (DE) (519.14 KB - PDF)

View

eesti keel (ET) (516.76 KB - PDF)

View

ελληνικά (EL) (711.69 KB - PDF)

View

français (FR) (516.17 KB - PDF)

View

italiano (IT) (519.32 KB - PDF)

View

latviešu valoda (LV) (690.36 KB - PDF)

View

lietuvių kalba (LT) (656.6 KB - PDF)

View

magyar (HU) (676.17 KB - PDF)

View

Malti (MT) (688.96 KB - PDF)

View

Nederlands (NL) (518.44 KB - PDF)

View

polski (PL) (691.01 KB - PDF)

View

português (PT) (520.24 KB - PDF)

View

română (RO) (650.61 KB - PDF)

View

slovenčina (SK) (680.33 KB - PDF)

View

slovenščina (SL) (673.42 KB - PDF)

View

Suomi (FI) (516.88 KB - PDF)

View

svenska (SV) (517.53 KB - PDF)

View

Product information

български (BG) (1.27 MB - PDF)

View

español (ES) (624.63 KB - PDF)

View

čeština (CS) (1.06 MB - PDF)

View

dansk (DA) (670.18 KB - PDF)

View

Deutsch (DE) (623.7 KB - PDF)

View

eesti keel (ET) (616.86 KB - PDF)

View

ελληνικά (EL) (1.25 MB - PDF)

View

français (FR) (684.89 KB - PDF)

View

hrvatski (HR) (752.92 KB - PDF)

View

íslenska (IS) (612.91 KB - PDF)

View

italiano (IT) (613.84 KB - PDF)

View

latviešu valoda (LV) (1.15 MB - PDF)

View

lietuvių kalba (LT) (786.25 KB - PDF)

View

magyar (HU) (1.03 MB - PDF)

View

Malti (MT) (975.04 KB - PDF)

View

Nederlands (NL) (622.94 KB - PDF)

View

norsk (NO) (606.27 KB - PDF)

View

polski (PL) (1.08 MB - PDF)

View

português (PT) (679.29 KB - PDF)

View

română (RO) (733.17 KB - PDF)

View

slovenčina (SK) (1.04 MB - PDF)

View

slovenščina (SL) (1.03 MB - PDF)

View

Suomi (FI) (610.22 KB - PDF)

View

svenska (SV) (667.87 KB - PDF)

View

Latest procedure affecting product information: IAIN/0024/G

18/01/2017

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Product details

Name of medicine
LeukoScan
Active substance
sulesomab
International non-proprietary name (INN) or common name
sulesomab
Therapeutic area (MeSH)
  • Osteomyelitis
  • Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
VO4D

Pharmacotherapeutic group

Diagnostic agents

Therapeutic indication

This medicinal product is for diagnostic use only.

LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.

LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.

Authorisation details

EMA product number
EMEA/H/C/000111
Marketing authorisation holder
Immunomedics GmbH

Otto-Röhm-Straße 69
D-64293 Darmstadt
Germany

Marketing authorisation issued
14/02/1997
Revision
7

Assessment history

This page was last updated on

How useful do you find this page?